Finance Forex

OxyContin maker reportedly had plan to sell opioid treatment drugs as well

OxyContin Maker Reportedly Had Plan To Sell Opioid Treatment Drugs As Well paper is one regarding those Finance, Forex groups, published with our writer Erick Emerson with February 1, 2019, these blogpost can search just as that tags list drugs, maker, opioid, OxyContin, Plan, Reportedly, sell, treatment. I am satisfied to satisfied you moreover providing the anothers paragraph from finance moreover I always updating this blogpost daily.

OxyContin maker Purdue Pharma hatched a secret plan to get into the business of selling drugs to treat the opioid addiction that its own products fueled, newly unsealed court filings allege.

The explosive claim comes in a lawsuit filed by the state of Massachusetts, which accuses Purdue owners the Sackler family and company honchos of creating and then profiting from opioid epidemic “through a web of illegal deceit.”

Starting in 2014, the company began discussing a plan called “Project Tango” to expand into opioid addiction treatments, the suit alleges.

In internal documents about the scheme, staff acknowledged “what Purdue publicly denied for decades: that addictive opioids and opioid addiction are ‘naturally linked,’” the suit charges.

An illustration of an “end-to-end” business model shows a funnel with “pain treatment” at the top and “opioid addiction treatment” at the bottom, while a graph shows the opioid abuse “market” had grown by a billion dollars between 2009 and 2014.

The plan never eventuated, but in 2016, the Sacklers met to discuss a “revised” version of Tango — selling the overdose antidote Narcan, which they identified as a “complementary” product to Purdue opioids, according to the suit.

The following year, future Purdue CEO Craig Landau proposed capitalizing on the crisis in a different way — while other companies were abandoning opioids amid the addiction epidemic, he said Purdue should double down and become an even more dominant opioid seller, the suit alleges.

He also noted in his presentation that the company’s board — the majority of which is controlled by the Sacklers — operated as its “de facto” CEO, even as the company denied that the family members held any “management positions” in the business.

Indeed, the suit alleges the Sacklers voted to pay their family more than $4 billion from Purdue’s opioid profits between 2007 and 2018.

The suit also alleges that the company collected, but sat on, details of suspected “problem prescribers” — with staffers reporting the doctors to the board by name, “along with the exact number of prescriptions and dollars of revenue each provided to Purdue.”

Meanwhile, the company hired consulting firm McKinsey to study how it could get doctors to prescribe more Oxy and to keep patients on opioids longer, the document charges.

The consultants “urged” the Sacklers to demand sales reps increase their visits to doctors — especially to the “most prolific opioid prescribers” — while also helping advise on how to “counter the emotional messages from mothers with teenagers that overdosed in [sic] OxyContin,” the suit claims.

In a lengthy response, Purdue said the suit was part of “a continuing effort” to blame the company “for the entire opioid crisis, and try the case in the court of public opinion rather than the justice system.”

Among the Massachusetts Attorney General’s most “egregious mischaracterizations,” the company writes, was “casting in a negative light Purdue’s due diligence on a potential acquisition of a drug for the treatment of addiction that was already on the market; even though the company never actually made the acquisition.”

This report originally appeared on NYPost.com.

You maybe want to gather anothers chapter finance just after our similar chapter or you might want to go through just as noted chapter, I'm always writting those finance section routine for advise along with suggest also technique in order to manage our finance along with living those financial freedom. These paper is posted on Erick Emerson with that title OxyContin Maker Reportedly Had Plan To Sell Opioid Treatment Drugs As Well.

Related posts of "OxyContin maker reportedly had plan to sell opioid treatment drugs as well"

Avis Stock Is Spiking Higher Because People Still Need to Rent Cars

Avis Budget Group stock (ticker: CAR) is racing ahead more than 17% on Thursday, following the vehicle rental firm’s upbeat fourth-quarter earnings and full-year outlook. The Back Story. Last year wasn’t a great one for Avis, and the shares are down more than 26% in the trailing 12-month period. The company started 2018 on a...

Traders Net-Short Decreased from Last Week

30.6% OF TRADERS ARE NET-LONGUS 500: Retail trader data shows 30.6% of traders are net-long with the ratio of traders short to long at 2.26 to 1. In fact, traders have remained net-short since Jan 07 when US 500 traded near 2527.99; price has moved 7.1% higher since then. The number of traders net-long is...

Dow Falls as Wall Street Gets No Boost From State of the Union

Here Are 3 Hot Things to Know About Stocks Right Now The Dow Jones Industrial Average declined on Wednesday after closing with gains for three consecutive sessions. The S&P 500 has risen for five straight days. General Motors Co. (GM) reported stronger-than-expected fourth-quarter earnings and confirmed its 2019 profit outlook. Shares rose 2%. Walt Disney Co. (DIS)  was...

New Fortress Energy Shares Gain After Rough Nasdaq Debut

Shares of New Fortress Energy LLC (NFE) were up 5.20% to $13.76 Friday, one day after the global energy infrastructure company made its Nasdaq debut. New Fortress Energy, the first IPO of the year, got off to a rough start on Thursday and closed at $13.07 a share, after going public at $14, $1 below its proposed...

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.